CPLHA
Csl Finance PLC
๐ฆ๐บ ASX
๐ Overview
๐ Performance
๐ต Cost
๐ค Advanced
๐จโ๐ฉโ๐งโ๐ฆ Community
๐
N/A
Annual Growth
5 years average annual growth
๐ต
$ 500
Minimum Order
Due to regulatory requirements
๐
0
Pearlers Invested
Since January 2020
๐ Overview
Key information
๐ Fund Overview
3.850%Snrgtdnotes Mat 27-Apr-2027 Min Cons $5Ht Nc
๐ Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
๐๏ธ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out โ๐ต Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out โโฑ๏ธ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out โ๐ต Costs
๐ผ
N/A
Management Fee
Included in unit price, not charged by Pearler
๐ธ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
๐ธ Net fee calculator๐ค Advanced information
Technical Info
๐ฉโ๐ฉโ๐ฆ Community Insights
How our community is investing
๐ Pearlers invested in CPLHA
0
๐ Total Capital Earnings
N/A
๐ Average investment frequency
N/A
๐ต Average investment amount
N/A
โฐ Last time a customer invested in CPLHA
N/A
CPLHA investor breakdown
๐ต Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
๐ถ Age of investors
18 - 25
26 - 34
35 - 90
๐ Legal gender of investors
Female
Male
Pearlers who invest in CPLHA also invest in...
Want more shares? Try these...
CLEO Diagnostics Ltd. is a medical diagnostics/devices company which mainly focuses on the development of non-invasive blood based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company is headquartered in Melbourne, Victoria. The company went IPO on 2023-08-22. Its principal activities involve the development and patent of a blood test for the detection of ovarian cancer. The company focuses on bringing to market a blood test for the early diagnosis of ovarian cancer based on the novel CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in non-malignant disease. The company is advancing the availability of its blood test, under a modular execution strategy, which is designed to address all ovarian cancer detection markets with specific tests, including surgical triage, recurrence, high risk, and early-stage screening. The company has developed a three-phased product development strategy that delivers three related tests for ovarian cancer detection: Triage Test, Recurrence Test, and Screening Test. Triage Test is a pre-surgical test to determine the likelihood that a pre-surgical ovarian mass in a patient not yet referred to an oncologist, is malignant.
๐ Share price
$0.37 AUD
Coppermoly Ltd. is an exploration and development company, which explores and evaluates copper, gold, molybdenum and gold deposits in Papua New Guinea. The company is headquartered in Brisbane, Queensland. The company went IPO on 2008-01-31. The Companyโs projects are located in North Queensland (Australia). The firm is focused on copper and gold projects in the Mount Isa Inlier. The Companyโs Mt Isa projects include two granted tenements and five applied tenements, four of them with IOCG potential are located within the Eastern Succession and one for Isa style copper system sits in the Western Foldbelt. The company holds contiguous EPM 27835 (Foxes Creek) and EPM 27836 (Mount Tracey), located over 55 km south southwest (SSW) of Cloncurry, and are situated along the north-south striking Cloncurry Fault. Its Windy Hill Prospect is located approximately 80 kilometers (km) south-west of Cloncurry. Its Jessievale application is located about 50 km north of Cloncurry. The application consists of 11 subblocks and sits next to its Mt Malakoff Project (EPM 28853).
๐ Performance (5Yr p.a)
10.00%
๐ Share price
$0.01 AUD
๐ HIGH PRICE GROWTH
โ๏ธ MINING